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1,2,3,4-tetrahydroissoquinolines as inhibitors of HIV-1 integrase and 
human LEDGF/p75 interaction  
Abstract 
Alkaloids are a class of organic compounds with a wide range of biological properties, including 
anti-HIV activity. The 1,2,3,4-tetrahydroisoquinoline is a ubiquitous structural motif of many 
alkaloids. Using a short and an efficient route for synthesis, a series of 1,2,3,4-
tetrahydroisoquinolines/isoquinolines was developed. These compounds have been analysed for 
their ability to inhibit an important interaction between HIV-1 integrase enzyme (IN) and human 
LEDGF/p75 protein (p75) which assists in the viral integration into the active genes. A lead 
compound 6d is found to inhibit the LEDGF/p75-IN interaction in vitro with an IC50 of ~10 µM.  
Molecular docking analysis of the isoquinoline 6d reveals its interactions with the LEDGF/p75-
binding residues of IN. Based on an order of addition experiment, the binding of 6d or LEDGF/p75 
to IN is shown to be mutually exclusive. Also, the activity of 6d in vitro is found to be unaffected 
by the presence of a non-specific DNA. As reported earlier for the inhibitors of LEDGF/p75-IN 
interaction, 6d exhibits a potent inhibition of both the early and late stages of HIV-1 replication. 
Compound 6d differing from the known inhibitors in the chemical moieties and interactions with 
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CCD could potentially be explored further for developing small molecule inhibitors of 
LEDGF/p75-IN interaction having a higher potency.  
Introduction 
HIV-1 integrase (IN) catalyses the integration of a viral DNA (vDNA) into the host genomic DNA 
(gDNA) during the early stage of replication. [1-4] Although IN can exist as a monomer, dimer, 
tetramer and a higher oligomer in the solution, it is the tetramer of IN that binds to the LTR (long 
terminal repeat) termini of the vDNA, forming an uncleaved intasome (UI). The UI catalyses a 3` 
end processing reaction resulting in the formation of cleaved intasome (CI) in the cytoplasm. The 
CI captures the gDNA to form a transient target capture complex (TCC) in the nucleus. The IN in 
the TCC catalyses the strand transfer reaction, covalently linking the 3`ends of the vDNA to the 
gDNA and forming a strand transfer complex (STC). HIV-1 preferentially integrates into the 
actively transcribing genes of the gDNA.[5,6] An important co-factor of IN that is required for 
vDNA integration into the active genes is the human transcriptional co-activator LEDGF/p75 (lens 
epithelium-derived growth factor).[7-11] Amino acid residues 347- 429 at the C-terminus of 
LEDGF/p75 termed as the integrase binding domain (IBD)[12-14] binds to IN in the PIC (pre-
integration complex), while the PWWP domain at the N-terminus interacts with the chromatin,[15-
18] making LEDGF/p75 as a bimodal tether for integration of HIV-1 into the active genes[19,20]. Co-
crystal of IBD and CCD (catalytic core domain) of IN reveals that two interhelical loops of IBD, 
comprised of the residues 364-368 and 405-408, respectively, interact with the LEDGF-binding 
site at the dimer interface of CCD of IN.[13,21,22] The hydrophobic interaction between I365 of IBD 
and the hydrophobic pocket formed by L102, A128, A129, W132 of one monomer and T174, 
M178 of the other monomer of IN dimer, is one of the three critical interactions in the LEDGF/p75-
IN complex. The hydrophobic interaction between W131 of IN and F406, V408 of IBD forms the 
second critical interaction. A bidentate H-bond is formed between the side chain carboxyl of D366 
of IBD and the main chain amides of E170, H171 of IN. A D366N mutation in IBD abrogates the 
formation of a LEDGF/p75-IN complex, highlighting the importance of the third critical 
interaction. These critical interactions in the LEDGF/p75-IN complex are targeted by small 
molecule inhibitors for discovering anti-HIV drugs.  
A halogen containing quinoline molecule, CX04328, was developed as the first LEDGIN 
(inhibitor of LEDGF/p75-IN interaction) and demonstrated to be effective at micro-molar 
concentration in inhibiting the interaction of LEDGF/p75 and IN in vitro, as well as, HIV-1 
infection in a mammalian cell line.[23] Later studies have demonstrated that LEDGINs such as BI-
1001, GS-A, GS-B, CX14442, GSK1264 are allosteric IN inhibitors (ALLINIs) as they 
allosterically stabilize an inactive oligomeric form of IN and interfere with IN-vDNA assembly, 
while preformed IN-vDNA complexes are refractory.[24-30] The ALLINIs present during the late 
phase of HIV-1 replication induce a premature multimerization of IN (a LEDGF/p75-independent 
effect) resulting in the production of less infectious virions that are defective for reverse 
transcription, nuclear import of PIC and integration.[31-33] The LEDGINs such as GS-A and GS-B 
also qualify as non-catalytic site IN inhibitors (NCINIs) as they interfere with IN-vDNA 
assembly.[24, 27] The LEDGF/p75-independent effects of these molecules are found to contribute 
to their higher potency for inhibiting HIV-1 replication. 
In this study, starting with a series of 1,2,3,4-tetrahydroisoquinolines, a non-halogenated 
isoquinoline compound 6d has been identified as a lead molecule for inhibiting LEDGF/p75-IN 
interaction. The chosen tetrahydroisoquinoline moiety is present in a number of isoquinoline based 
alkaloid natural products having antitumor, anti-microbial, anti-inflammatory, anti-analgesic and 
anti-HIV-1 activity.[34-36] A short and efficient route for the synthesis of substituted 1,2,3,4-
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tetrahydroisoquinolines was developed in an earlier study and shown to yield pure compounds 
suitable for biological evaluation.[37,38] Following an initial screening of the series of 
tetrahydroisoquinolines, a lead compound 6d with an IC50 of ~10 µM for inhibiting in vitro 
interaction between recombinant LEDGF/p75 and IN was obtained. Compared to the LEDGF/p75-
IN inhibitors reported earlier,[23-30] 6d differs in: having an isoquinoline rather than a quinoline 
core, lacking a halogen or sulphur atom and having an ester rather than a carboxyl moiety 
(supplementary Figure 1). As seen in the three dimensional structures of known LEDGINs bound 
to the CCD dimer,[23,24] molecular docking analysis shows 6d interacting with the LEDGF/p75 
binding site of a CCD dimer, although the type of interactions is different. Both IN and 
LEDGF/p75 can bind to DNA in a sequence independent manner,[39-43] however, the presence of 
a non-specific DNA did not alter the inhibitory activity of 6d in vitro. Also, the pre-formed 
LEDGF/p75-IN complexes could not be disrupted by 6d in vitro, indicating a requirement for 6d 
to access the LEDGF/p75-binding site on IN for having an inhibitory effect. Interaction of 
LEDGF/p75 and IN in the cell lysates, as well as, the early and late stages of HIV-1 replication is 
efficiently inhibited by 6d. Taken together, the unique features of 6d described here could 
potentially be used for developing inhibitors of LEDGF/p75-IN interaction having a higher 
potency. 
Materials and Methods 
Synthesis of 1,2,3,4-tetrahydroisoquinoline compounds 
The synthesis of 1,2,3,4-tetrahydroisoquinoline compounds 1a-1m (supplementary figure 2) was 
performed as described earlier. [37,38] The reduced ester moiety of 1a (labelled 4a) and rearranged 
aromatization of compounds 1a, 1d (labelled 6a, 6d) were synthesized as described in the 
supplementary material.  
In vitro pull-down assay 
The pull-down assay using a purified C-terminus His-tagged IN (His-IN) and a N-terminus GST 
tagged IBD (Integrase Binding Domain, GST-IBD) or a N-terminus GST tagged full length 
LEDGF/p75 (GST-p75) was performed as described earlier.[44] Briefly, in a 150 µl of phosphate 
pull-down buffer (PPD buffer) having 50 mM Phosphate buffer (pH 6.5), 150 mM NaCl, 2 mM 
MgCl2, 25 mM Immidazole and 0.1% NP-40, with or without indicated amount of a given 
compound, a 3 µg of His-IN was added and incubated at 37oC for 10 min. This was followed by 
addition of a 3 µg of GST-IBD or GST-p75 and incubation was continued at 37oC for another 10 
min. The formed complexes were pull-down by binding to the Ni sepharose 6 Fast flow beads (GE 
Healthcare) for 30 min at room temperature. The bound complexes were eluted in the PPD buffer 
containing 400 mM Immidazole and resolved on a 10% SDS-PAGE gel. Intensity of the coomassie 
blue stained protein bands was quantified using an Image Lab Software 4.0 (Bio-Rad). Stock 
solution of all the compounds were prepared in DMSO. The required dilutions of the compounds 
were prepared in the PPD buffer just prior to the assay. 
Pull-down of ectopically expressed proteins from a mammalian cell lysate 
Pull-down of a Flag-tagged IN (Flag-IN) and a HA-tagged LEDGF/p75 (HA-p75) over-expressed 
in the HEK293T cell line was performed as described earlier,[45,46] with slight modifications. Cells 
over-expressing either a Flag-IN or HA-p75, were lysed in a 300 µl of the lysis buffer (500 mM 
NaCl, 50 mM HEPES (pH 7.8), 0.5% Triton-X-100, 5% glycerol, 2 mM MgCl2), to this 1.2 ml of 
a binding buffer (50 mM HEPES (pH7.8), 5% glycerol, 2 mM MgCl2) with or without indicated 
amount of 6d was added. The mixture was nutated at 4oC for 4 h to allow binding of the compound. 
This was followed by the addition of a cell lysate containing the other protein partner and the 
nutation was continued at 4oC for 12 h, for the complex to form. Anti-Flag beads (Clontech) were 
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added to the mixed lysates and nutated at 4oC for additional 2 h. Beads were washed with buffer 
containing 150 mM NaCl, 50 mM HEPES (pH7.8), 0.1% Triton-X-100, 0.1% NP-40, 5% glycerol 
and 2 mM MgCl2 to remove any non-specific proteins. The proteins bound to the beads were eluted 
in a SDS-PAGE loading buffer and resolved on a 10% SDS-PAGE gel. The Flag-IN and HA-p75 
bands were detected on a Western blot using anti-Flag (Clontech) and anti-HA (Thermo Scientific) 
antibodies, respectively. 
Infection of pseudo-typed HIV-1 
The production of NLX-Luc-VSVg virus, setting up of infection and measuring of luciferase 
activity at 48 h post-infection, in the HEK293T cells, were performed as described earlier,[47] with 
slight modifications. The growth media on HEK293T cells containing the virus was collected at 
48 h post-transfection and stored at -80oC till it is used for infecting the cells. For analysing the 
effect of 6d on the late stage of replication, virus was generated by treating the HEK293T cells 
with 6d for the duration of transfection. In experiments analysing inhibition of the early stage of 
replication, cells were treated with 6d for 2 h prior to the addition of virus. To set up an infection 
using 70 µl of the virus, 0.08 – 0.12 million cells were plated per well of a 24-well plate at least 
12 h in advance. At 48 h post-infection, cells were harvested and the cell lysates was prepared 
using a 1X passive lysis buffer (Promega, cat. No. E1941). The luciferase activity in the lysates 
was measured using a D-luciferin sodium salt (Invitrogen, cat no. L2912). The luciferase activity 
was normalized to the concentration of the protein determined using a BCA reagent (Pierce, cat. 
No. 23221). The normalized luciferase activity in untreated infected cells was taken as 100% and 
that in 6d treated cells was determined accordingly. To measure the viability of cells treated with 
6d, addition of virus was omitted in the above infection protocol and at 48 h post-treatment with 
6d, a trypan blue exclusion method was used to determine the percent of live cells. The number of 
live cells in untreated wells was set as 100% and that in 6d treated cells was determined 
accordingly. 
Molecular docking analysis  
Molecular docking of 6d to CCD dimer of IN was performed using a Discovery Studio version 4.0 
software (Accelrys, USA). The three dimensional structure of CCD of IN (PDB accession 
1BL3)[48] was used as a receptor and 6d was used as a ligand, in the LibDock protocol. The known 
LEDGF/p75 interacting residues of IN[12,13,21]: L102, A128, A129, W131, W132, E170, H171, 
T174 and M178 were used to define the interaction sphere for docking. The best docked pose was 
ranked based on the LibDock score and binding energy and was used for determining the 
interactions between 6d and the CCD dimer. 
Statistical analysis 
Intensity of the bands corresponding to IBD or LEDGF/p75 over IN (ratio of IBD or LEDGF/p75 
to IN) was calculated to obtain the extent of complex formation in the pull-down assays. The 
IBD:IN ratio in the sample without compound was set to 100% binding and in those having 
compound was calculated accordingly. The concentration of a compound giving a 50% inhibition 
of the complex formation is determined to be its IC50. Data from at least three independent 
experiments has been used to obtain the standard error. 
Results and Discussion 
Tetrahydroisoquinolines can inhibit interaction between IBD and IN in vitro 
The first series of 1,2,3,4-tetrahydroisoquinoline compounds 1a-1m (supplementary Fig. 2) were 
tested in vitro for their ability to inhibit the interaction between His-IN and GST-IBD in the pull-
down assay. A serial double dilution of the compounds with a starting concentration of 24 mM 
was used in the initial screening and the in vitro assay was performed as described in the methods. 
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The IC50 of the compounds 1a-1m for inhibiting the formation of IBD-IN complex is shown in 
Table 1. Of all the compounds tested in this series, 1a is found to be the most potent as it has the 
least IC50 of ~80 µM (Fig. 1A). Although 1h has the second best IC50, 1d that differs from 1h only 
in the presence of an ethyl rather than a tert-butyl group on the ester moiety, did not show any 
inhibition even at the highest concentration tested in the in vitro assay. 
Increasing the potency of compounds by rearranged aromatization 
With the aim of increasing the potency of the compounds in the first series, either a reducing or an 
oxidizing condition was used as an additional step to the synthesis scheme and those compounds 
with an appreciable purity were tested in vitro. Reducing of the ester group on the best compound 
1a (IC50 ~80 µM) resulted in an alcohol containing derivative labelled as 4a (scheme 2, 
supplementary material), that has an IC50 greater than 24 mM, emphasizing the importance of an 
ester moiety for activity of the compound. Subjecting 1a to an oxidative condition (scheme 3, 
supplementary material) resulted in a rearranged aromatization and significantly enhanced the 
potency of the derivative labelled as 6a. Compound 6a showed the inhibition of IBD-IN complex 
formation with an IC50 of 20.2±8.1 µM (Fig. 1B). Interestingly, a similarly rearranged 
aromatization of 1d (that lacks any inhibitory activity, Table 1) resulted in a lead molecule 6d 
(ethyl-1-benzyl-7-methoxyisoquinoline-4-carboxylate) that is characterized further in this study. 
Compound 6d inhibited the interaction between IBD and IN with an IC50 of 10.4±3.8 µM (Fig. 
1C) and the interaction between IN and full-length LEDGF/p75 with an IC50 of 11.1±4.4 µM 
(Supplementary Fig 3). Thus, compared to 1d, a benzyl group at the 1st position of an unsaturated 
bicyclic system dramatically enhanced the ability of 6d for inhibiting the interaction between IBD 
and IN. 
Molecular docking shows interaction of 6d with the critical residues of CCD 
In order to gain insight into how 6d interacts with IN, molecular docking of 6d to CCD dimer of 
IN was performed as described in the methods. The interactions between 6d and CCD are 
summarized in table 2. The results of docking analysis indicate that 6d inhibits binding of IBD by 
sterically blocking access to the LEDGF/p75 binding site on IN (Fig. 1D), similar to the LEDGINs 
reported earlier. Co-crystal structures of the known LEDGINs with CCD[23-26,30] reveal H-bonds 
between the carboxyl moiety of the inhibitor and the backbone amides of E170, H171 and the side 
chain hydroxyl group of T174, while 6d has pi-donor H-bonds between the isoquinoline core and 
the side chain hydroxyl group of T174. In addition, methoxy and ester moieties of 6d make carbon 
H-bond with the backbone amides of Q95 and A128, respectively. The quinoline core of known 
LEDGINs has a hydrophobic interaction with one face of the hydrophobic pocket of CCD dimer 
comprised of residues Q95, T124, T125, A128, while the isoquinoline core of 6d has a 
hydrophobic interaction with A98, A169 and T174. The ethyl group (in the ester moiety) of 6d is 
surrounded by the hydrophobic side chains of L102, W132 and M178. A pi-anion charge 
interaction is present between the benzyl group of 6d and the side chain carboxyl group of E170. 
Overall, the binding of 6d to CCD dimer while being similar to that of known LEDGINs, seems 
to offer sufficient differences in the type of interactions at the LEDGF/p75 binding site that could 
potentially be explored further. It has been shown earlier that a virus resistant to LEDGINs carries 
one or more of the following mutations: Y99H, L102F, T124N, A128T, A129T, H171T, T174I in 
CCD, with A128T being the most common resistance mutation.[32,49,50] Owing to the overlap in 
the residues of CCD interacting with 6d and known LEDGINs, similar mutations in IN can be 
expected to result in an emergence of resistance to 6d. 
Binding of IBD, 6d to IN is mutually exclusive 
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To gain a further insight into the details of inhibition by 6d, IBD-IN or LEDGF/p75-IN complexes 
were formed in the absence of 6d and in the absence or presence of a non-specific DNA and 
activity of 6d on such complexes was analysed. First, displacing of IBD in the complex by 6d 
would require accessing the same interacting residues on CCD, which might be feasible if 6d can 
also bind at a secondary site on IN and induce conformational changes in CCD that reduce the 
affinity for IBD. Second, since both IN and LEDGF/p75 are non-specific DNA binding 
proteins,[39-43] it is possible that a DNA bound protein has an altered affinity for 6d or DNA by 
itself binds to 6d, consequently influencing the activity of 6d. Following the formation of a IBD-
IN complex at 37oC for 10 min, 150 µM of 6d (15 times the IC50) was added and pull-down assay 
was performed as described in the methods. As can be seen in Fig. 2A, 6d did not disrupt a pre-
formed complex (lane 3) and the extent of pre-formed complex remained similar to that formed in 
the absence of 6d (lane 1), while the interaction of IBD with a 6d bound IN is completely inhibited 
(lane 2). These results indicate that the binding of IBD, 6d to IN might be mutually exclusive due 
to an overlap at the site of interaction. Although the possibility of 6d binding at a secondary site 
on IN is not ruled out, it nonetheless does not seem to alter the affinity for IBD. Incubating IN with 
a non-specific DNA (1 µg of plasmid pUC18) at 37oC for 10 min, prior to addition of 6d, did not 
affect the ability of compound to inhibit IBD-IN interaction (lane 4). Formation of a IBD-IN 
complex in the presence of a non-specific DNA (lane 5) or addition of a non-specific DNA to a 
pre-formed IBD-IN complex (lane 6), prior to the addition of 6d, did not result in the disruption 
of the complex. Similar results were obtained when IBD was replaced with a full length 
LEDGF/p75 (GST-p75) (Fig. 2B). 
Reversing the order of addition of protein partners by incubating IBD with 6d, prior to the addition 
of IN (Fig 2A, lane 7) or a non-specific DNA bound IN (lane 8), did not result in any inhibition 
by 6d. In this case, it may be speculated that binding of 6d to IBD at a site(s) other than the inter 
helical loops involved in the interaction with IN[13,21,22] decreases the effective concentration of 6d 
that is required to inhibit complex formation. Although full length LEDGF/p75 binds to a non-
specific DNA,[42,43] addition of 6d to a DNA bound LEDGF/p75 prior to that of IN (Fig 2B, lane 
9) or vice versa (lane 10), did not result in an inhibition of the LEDGF/p75-IN complex formation. 
These results indicate that neither the presence of a non-specific DNA nor the binding of DNA by 
any of the protein partners, at any stage of the complex formation, interferes with the inhibitory 
activity of 6d in vitro.  
Inhibition of interaction in the presence of cellular proteins  
Prior to testing the ability of 6d to inhibit HIV-1 infection, the inhibitory activity of 6d on an 
interaction between the ectopically expressed proteins in a mammalian cell lysate was analysed. 
A lysate of HEK293T cells overexpressing either a Flag-IN or a HA-p75 was treated with 150 µM 
of 6d prior to the addition of a lysate containing the other protein partner and the formation of 
LEDGF/p75-IN complex was analysed as described in the methods. Treating the lysate having 
Flag-IN with 6d, prior to mixing with the lysate containing HA-p75 resulted in an 81±10% 
reduction in the amount of LEDGF/p75-IN complex formed (Fig. 3A, lane 1), as compared to that 
formed in the absence of 6d (lane 3). Treating the lysate having HA-p75 with 6d, prior to mixing 
with the lysate having Flag-IN resulted in a 71±12% reduction in the amount of LEDGF/p75-IN 
complex formed (lane 2). The inhibition of complex formation observed in Fig 3A, lane 2 (pre-
treating cell lysate containing LEDGF/p75 with 6d) is in contrast to a lack of inhibition shown in 
Fig. 2B, lanes 7-9 (pre-treating purified recombinant LEDGF/p75 with 6d) and can be explained 
if the speculated secondary site on LEDGF/p75 for binding of 6d is masked by other cellular 
proteins in the lysate and hence the effective concentration of 6d remains unaltered. The results 
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shown in figures 2 and 3 indicate that 6d can inhibit the interaction between IN and LEDGF/p75 
inside the cell and can be expected to inhibit HIV-1 infection.  
Inhibition of HIV-1 infection by 6d 
LEDGINs are known to affect the early stage of HIV-1 replication by inhibiting assembly of IN-
vDNA complex, as well as, the interaction between LEDGF/p75 and IN at the integration step and 
also affect the late stage of replication by stabilizing the aberrant multimerization of IN in the 
newly formed virions that consequently become less infectious.[23-33] ALLINIs inhibit multiple 
steps of viral replication such as Prior to analysing the effect of 6d on HIV-1 infection, the viability 
of HEK293T cells treated with 0, 12.5, 25, 50, 100, 150 and 200 µM of 6d was measured as 
described in the methods. No cytotoxicity was observed up to 50 µM of 6d (Fig. 3B, filled squares) 
however, a 30±5, 55±7 and 63±3% drop in live cells was noticed in the samples treated with 100, 
150 and 200 µM, respectively, giving a CC50 of ~140 µM. For analysing the effect of 6d on the 
early stage of replication, the cells were treated with 0, 12.5, 25 and 50 µM of 6d prior to the 
infection. The normalized luciferase activity in the cell lysate was used to determine the levels of 
infection. As shown in Fig. 3B, a 0, 19±8 and 63±7 % inhibition of infection was observed with 
12.5, 25 and 50 µM concentration of 6d (Fig. 3B, filled circles). Using the linear range of the 
inhibition curve (Fig 3B), an IC50 of ~42.5 µM for 6d has been obtained. Based on these results, 
6d is determined to have a selectivity index (CC50/IC50) of 3.3. Infectivity of virus generated in the 
presence of 0, 12.5, 25, 50 µM of 6d was measured to assess the inhibition of the late stage of 
replication. A noticeable increase in the inhibitory potency of 6d could be seen as a 33±2, 41±8 
and 75±7 % decrease in the infectivity of the virus generated in the presence of 12.5, 25 and 50 
µM of 6d was observed (Fig. 3B, filled triangles). An IC50 of ~31 µM, with a selectivity index of 
4.5, for inhibition of late stage of replication has been obtained. At concentrations above 50 µM, 
the cytotoxic effects of 6d interfered with the analysis of its inhibitory effects. These results 
indicate that, similar to the known LEDGINs,[23-30] 6d could also be affecting both the 
LEDGF/p75-dependent integration rather than steps such as reverse transcription, nuclear import 
of PIC, during early stage of replication, while the virus generated in the presence of 6d could be 
less infectious due to an effect on the maturation stage, arising from the aberrant multimerization 
of IN (a LEDGF/p75-independent effect).  
Conclusion 
In conclusion, compound 6d (ethyl-1-benzyl-7-methoxyisoquinoline-4-carboxylate) that 
efficiently inhibits the interaction between LEDGF/p75 and IN in vitro, as well as, HIV-1 infection 
in a cell line, has been identified as a lead isoquinoline molecule in this study. The order of addition 
experiment indicates an overlap in the binding site for IBD, 6d on CCD of IN. Similar to the known 
LEDGINs, [23-33] 6d shows an effect on the early and late stages of HIV-1 replication. In addition 
to the chemical differences between 6d and already known LEDGINs (supplementary figure 1), 
molecular docking indicates a possibility for sufficient differences in the type of interactions 
between 6d and the residues of CCD (Table 2). Of interest, is the ethyl group in the ester moiety 
of 6d which fits into the hydrophobic pocket of CCD that is occupied by the side chain of one of 
the critical residue I365 of LEDGF/p75. In a recent study, we have shown that M178 of CCD 
might probably be the first residue from the hydrophobic pocket of IN to interact with I365 of 
LEDGF/p75.[44] Since the mutation of M178 is shown to result in a catalytically inactive IN,[51] as 
well as, result in an abrogation of its interaction with LEDGF/p75, [44] the features of 6d imparting 
interaction with M178 could potentially be exploited further for developing a small molecule 
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Figure Legends 
Figure 1. In vitro pull-down analysis. The figure shows pull-down assays performed using 
recombinant IN and IBD in the presence of the compounds. Panels A, B and C show assay 
performed using compounds 1a, 6a and 6d, respectively. The concentration (mM or µM) of the 
compound in the assay samples is indicated at the top of the respective lanes. The numbers below 
each lane represent the percent inhibition of formation of IBD-IN complex by the compound, 
calculated with respect to the assay having no compound. Bands corresponding to IBD and IN are 
indicated. The picture in panel C is assembled from two separate gels. Panel D shows the 
interactions between 6d and the residues of CCD of IN in the docked complex of 6d-CCD. The 
amino acid residues are indicated by solid black lines, the structure of 6d is shown with gray lines 
and the dashed lines represent the interactions between 6d and CCD. 
Figure 2. Pre-formed complexes are not disrupted by compound 6d. Panels A and B show the 
formation of IN-IBD and IN-p75 complexes respectively. The order of addition of the components 
in the pull-down assay is indicated at the top of respective lane. The symbol ‘>’ indicates sequential 
addition and ‘+’ indicates incubation of components together prior to the addition of the next 
component in the assay. Letter D denotes inclusion of a non-specific DNA to the assay. Bands 
corresponding to IBD, p75 and IN are indicated to the right. Lane numbers are indicated below the 
gel picture. 
Figure 3. Compound 6d inhibits LEDGF/p75-IN interaction in the mammalian cell. Panel A 
shows the Western blot analysis of the complex pull-down from the cell lysates using anti-Flag 
beads. The ‘IN+6d’ in lane 1 represents treatment of the cell lysate having Flag-IN with 6d, prior 
to addition of lysate containing HA-p75. The ‘p75+6d’ in lane 2 represents treatment of the cell 
lysate having HA-p75 with 6d, prior to addition of lysate containing Flag-IN. The ‘-6d’ in lane 3 
represents the LEDGF/p75-IN interaction obtained by mixing lysates expressing either one of the 
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protein partners without 6d treatment. Top part shows blotting of the pull-down complex using 
anti-HA antibodies for analysing HA-p75. Bottom part shows the blotting of pull-down complex 
using anti-Flag antibodies for analysing Flag-IN. Panel B shows the inhibition of HIV-1 infection 
by 6d. The concentration of 6d in µM (0, 12.5, 25 and 50) used in the analysis is indicated on the 
X-axis.  Dotted line (filled square marks) indicates the percent of live cells in samples treated with 
different concentrations of 6d. Dashed dot line (filled circle marks) and dashed line (filled triangle 
marks) represent the percent inhibition of the early and late stages of HIV-1 replication by 6d, 
respectively.  
Table Legends 
Table 1. IC50 of the tetrahydroisoquinolines for inhibition of the interaction between IN and IBD. 
‘N.I’ indicates no inhibition with 24 mM concentration of compound; >24 mM indicates IC50 in 
range of 25-34 mM and >>24 mM indicates IC50 in range of 35-60 mM; ‘N.T’ indicates compound 
not tested in the assay due to insolubility of the compound. 
Table 2. Interactions between CCD and compound 6d. Compound is indicated as molecule 1 and 
the two chains of CCD dimer are denoted as A and B. Positions of H, C and O atoms on compound 
and those of amino acid residues in IN are mentioned against each interaction. 




Figure 2. Pre-formed complexes are not disrupted by compound 6d. 
 






Table 1. IC50 of 1,2,3,4-tetrahydroisoquinolines. 
Compound IC50 (mM) Compound IC50 (mM) 
1a 0.081±0.01 1e >> 24 mM 
1h 1.63±0.02 1i > 24 mM 
1k 2.23±0.15 1j > 24 mM 
1b 7.07±0.62 1m >> 24 mM 
1f 10.03±2.11 1d N.I 
1l 12.22±1.4 1g N.T 




Table 2. Interactions between CCD and compound 6d. 
CCD - 6d complex Type of Interaction 
Molecule 1:H29 - B:GLN95:O Carbon Hydrogen Bond 
Molecule 1:H39 - B:ALA128:O Carbon Hydrogen Bond 
A:GLU170:OE1 - Molecule 1 Pi-Anion 
A:THR174:OG1 - Molecule 1 Pi-Donor Hydrogen Bond 
A:THR174:OG1 - Molecule 1 Pi-Donor Hydrogen Bond 
A:THR174:CG2 - Molecule 1 Pi-Sigma 
A:THR174:CG2 - Molecule 1 Pi-Sigma 
Molecule 1:C24 - A:MET178 Alkyl 
Molecule 1:C24 - B:LEU102 Alkyl 
B:TRP132 - Molecule 1:C24 Pi-Alkyl 
B:TRP132 - Molecule 1:C24 Pi-Alkyl 
Molecule 1 - B:ALA98 Pi-Alkyl 
Molecule 1 - A:ALA169 Pi-Alkyl 
 
